Hopkinson Craig C., ER, D, CMO, reported an open-market or private sale at Alkermes plc. involving 171813.000000 shares for an estimated $5616807.51. Reported holdings after the transaction were 90983.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
EVP R&D, Chief Medical Officer
This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.00 to $32.9998. Full information regarding the number of shares sol…
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.00 to $33.52. Full information regarding the number of shares sold…
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.00 to $34.07. Full information regarding the number of shares sold…
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.00 to $36.05. Full information regarding the number of shares sold…
These options are fully vested in accordance with their terms.
Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.
Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023.
0 other filings
0 recent txs